The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.

Constantine S. Tam,Andrew W. Roberts,Mary Ann Anderson,Sarah-Jane Dawson,Rodney J. Hicks,Christiane Pott,David Westerman,Glenda Burke,Sarah Kamel,Martin Dreyling,Mark A. Dawson,John F. Seymour

The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.

2016

Constantine S. Tam
Andrew W. Roberts
Mary Ann Anderson
Sarah-Jane Dawson
Rodney J. Hicks
Christiane Pott
David Westerman
Glenda Burke
Sarah Kamel
Martin Dreyling
Mark A. Dawson
John F. Seymour

7548Background: The targeted agents ibrutinib (IB) & venetoclax (A; ABT-199) individually achieve response rates of 68-75% in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL...

Keywords:

Oncology
Refractory Mantle Cell Lymphoma
Medicine
Ibrutinib
Internal medicine
Pathology
Venetoclax
in patient
relapsed refractory
Refractory
Mantle cell lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations